GlaxoSmithKline (GSK) Price & Analysis

Compare

1,145 Followers

GSK Stock Chart & Stats

1972.50 p

-0.50 p(-0.04%)

At close: Jan 09 4:00 PM EST

1972.50 p

-0.50 p(-0.04%)

Day’s Range― - ―

52-Week Range1,242.50 p - 2,282.00 p

Previous CloseN/A

Volume367.08K

Average Volume (3M)8.54M

Market Cap

£78.94B

Enterprise Value93.32B

Total Cash (Recent Filing)£3.41B

Total Debt (Recent Filing)£17.72B

Price to Earnings (P/E)12.9

Beta1.08

Next Earnings

Apr 29, 2026

EPS Estimate

0.43

Next Dividend Ex-DateN/A

Dividend Yield3.29%

Share Statistics

EPS (TTM)0.26

Shares Outstanding4,065,726,300

10 Day Avg. Volume6,837,178

30 Day Avg. Volume8,542,213

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)4.51

Price to Sales (P/S)2.26

P/FCF Ratio12.41

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£2,044.55

Price Target Upside3.65% Upside

Rating ConsensusHold

Number of Analyst Covering12

EPS Forecast (FY)1.78

Revenue Forecast (FY)£33.78B

Bulls Say, Bears Say

Bulls Say

Capital Allocation And ProfitabilityOperating profitability surpassed expectations due to lower selling costs and higher royalty income, while a competitive dividend and active buyback program indicate shareholder-friendly capital allocation.

Market AdoptionSurvey shows community haematology/oncology physicians expect meaningful later-line use of Blenrep and greater willingness to prescribe it in community settings, supporting stronger commercial uptake.

Regulatory And Clinical ProgressPositive pivotal trial results for bepirovirsen that met the primary endpoint prompted a planned regulatory filing, creating a clear path to a substantial hepatitis B commercial opportunity.

Bears Say

Commercial Scalability And AccessAnalyst highlights doubts about scalability and access in emerging markets for certain products, which could restrict uptake and reduce potential revenue despite clinical promise.

Guidance And Margin HeadwindsFY26 guidance factors in a notable foreign exchange headwind and implies operating margins below prior mid-term targets, which limits expected earnings upside.

HIV Franchise Competition And Timing RiskCompetition in the US HIV market and uncertain timelines for late-stage HIV programs may create near-term sales pressure and constrain growth upside.

GlaxoSmithKline News

FDA approves GSK’s Lynavoy treatment of cholestatic pruritus in PBC patients

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved Lynavoy for the treatment of...

9h ago

GSK

Trump Trade: President issues short-term waiver of Jones Act

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

1d ago

AZN

BMY

Trump claims TrumpRx website offers lowest prices, review says not so, NYT says

President Trump and top federal health officials have repeatedly claimed that their new website, TrumpRx, offers Americans the...

1d ago

AZN

BMY

District court rules federal limits to vaccines not based on science, NYT says

Bostong U.S. District Judge Brian Murphy on Monday has sided with medical groups who argued that HHS Secretary...

3d ago

AZN

BMY

GSK announces FDA expands approved age indication of Arexvy

GSK (GSK) plc announced that the U.S. Food and Drug Administration has expanded the approved age indication of...

6d ago

GSK

AnaptysBio price target raised to $50 from $36 at Truist

Truist raised the firm’s price target on AnaptysBio (ANAB) to $50 from $36 and keeps a Hold rating...

10d ago

GSK

ANAB

GSK, Alfasigma announce agreement on worldwide rights for linerixibat

GSK (GSK) and Alfasigma announced a license agreement under which Alfasigma will acquire worldwide exclusive rights to develop,...

10d ago

GSK

Controversial Prasad leaving FDA, NYT reports

Dr. Vinay Prasad, who issued several controversial decisions, including having refused to accept Moderna’s (MRNA) application for a...

11d ago

AZN

BMY

AnaptysBio provides update on potential spin-off of biopharma operations

AnaptysBio (ANAB) provided an update on the potential spin-off of its biopharma operations. Intention to separate biopharma operations...

16d ago

GSK

ANAB

GSK completes acquisition of Rapt Therapeutics

GSK plc (GSK) announced the completion of its previously announced acquisition of Rapt Therapeutics (RAPT), a California-based, clinical-stage...

16d ago

GSK

RAPT

GSK Expands Treasury Stock with Latest Share Buyback

GlaxoSmithKline ( ($GB:GSK) ) has issued an update. GSK plc disclosed that it repurchased 445,000 of its ordinary...

4d ago

GSK Continues Share Buyback, Lifts Treasury Stock to 6.14% of Voting Rights

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK plc has repurchased 445,000 of its ordinary...

4d ago

GSK Wins Expanded U.S. Approval for Arexvy RSV Vaccine in High-Risk Adults Under 50

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has secured expanded U.S. approval for its RSV vaccine...

6d ago

GSK Expands Share Buyback, Lifts Treasury Stock to 6.13% of Voting Rights

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK plc has repurchased 790,000 of its ordinary shares on...

7d ago

GSK FAQ

What was GlaxoSmithKline’s price range in the past 12 months?

GlaxoSmithKline lowest share price was 1242.50 p and its highest was 2282.00 p in the past 12 months.

What is GlaxoSmithKline’s market cap?

GlaxoSmithKline’s market cap is £78.94B.

When is GlaxoSmithKline’s upcoming earnings report date?

GlaxoSmithKline’s upcoming earnings report date is Apr 29, 2026 which is in 41 days.

How were GlaxoSmithKline’s earnings last quarter?

GlaxoSmithKline released its earnings results on Feb 04, 2026. The company reported 0.255 p earnings per share for the quarter, beating the consensus estimate of 0.238 p by 0.017 p.

Is GlaxoSmithKline overvalued?

According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does GlaxoSmithKline pay dividends?

GlaxoSmithKline pays a Quarterly dividend of 16 p which represents an annual dividend yield of 3.29%. See more information on GlaxoSmithKline dividends here

What is GlaxoSmithKline’s EPS estimate?

GlaxoSmithKline’s EPS estimate is 0.43.

How many shares outstanding does GlaxoSmithKline have?

GlaxoSmithKline has 4,065,726,300 shares outstanding.

What happened to GlaxoSmithKline’s price movement after its last earnings report?

GlaxoSmithKline reported an EPS of 0.255 p in its last earnings report, beating expectations of 0.238 p. Following the earnings report the stock price went up 6.913%.

Which hedge fund is a major shareholder of GlaxoSmithKline?

Currently, no hedge funds are holding shares in GB:GSK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

GlaxoSmithKline Stock Smart Score

Neutral

Fundamentals

Return on Equity

37.19%

Trailing 12-Months

Asset Growth

2.78%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

GlaxoSmithKline

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GlaxoSmithKline (GSK) Earnings & Revenues

Historic Earnings Reports

GSK Stock 12 Month Forecast

Average Price Target

2,044.55 p

▲(3.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1356":"1,356 p","2751":"2,751 p","1704.75":"1,704.8 p","2053.5":"2,053.5 p","2402.25":"2,402.3 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2750,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.75K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2044.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.04K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.50K </span>\n  </div></div>","useHTML":true}}],"tickPositions":[1356,1704.75,2053.5,2402.25,2751],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2180,2223.846153846154,2267.6923076923076,2311.5384615384614,2355.3846153846152,2399.230769230769,2443.076923076923,2486.923076923077,2530.769230769231,2574.6153846153848,2618.4615384615386,2662.3076923076924,2706.153846153846,{"y":2750,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2180,2169.5807692307694,2159.1615384615384,2148.742307692308,2138.3230769230768,2127.903846153846,2117.484615384615,2107.0653846153846,2096.646153846154,2086.226923076923,2075.8076923076924,2065.3884615384613,2054.9692307692308,{"y":2044.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2180,2127.6923076923076,2075.3846153846152,2023.076923076923,1970.7692307692307,1918.4615384615386,1866.1538461538462,1813.8461538461538,1761.5384615384614,1709.2307692307693,1656.923076923077,1604.6153846153848,1552.3076923076924,{"y":1500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1409.239,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1411.642,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1405.876,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1475.122,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1373.507,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1357.949,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1423.411,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1643.684,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1750.87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1785.714,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1810.019,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1909.722,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2180,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >